Immunological Characteristics of Hyperprogressive Disease in Patients with Non-small Cell Lung Cancer Treated with Anti-PD-1/PD-L1 Abs
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Hyperprogressive disease (HPD) is a distinct pattern of progression characterized by acceleration of tumor growth after treatment with anti-PD-1/PD-L1 Abs. However, the immunological characteristics have not been fully elucidated in patients with HPD. We prospectively recruited patients with metastatic non-small cell lung cancer treated with anti-PD-1/PD-L1 Abs between April 2015 and April 2018, and collected peripheral blood before treatment and 7-days post-treatment. HPD was defined as ≥2-fold increase in both tumor growth kinetics and tumor growth rate between pre-treatment and post-treatment. Peripheral blood mononuclear cells were analyzed by multi-color flow cytometry to phenotype the immune cells. Of 115 patients, 19 (16.5%) developed HPD, 52 experienced durable clinical benefit (DCB; partial response or stable disease ≥6 months), and 44 experienced non-hyperprogressive progression (NHPD). Patients with HPD had significantly lower progression-free survival (p<0.001) and overall survival (p<0.001). When peripheral blood immune cells were examined, the pre-treatment frequency of CD39+ cells among CD8+ T cells was significantly higher in patients with HPD compared to those with NHPD, although it showed borderline significance to predict HPD. Other parameters regarding regulatory T cells or myeloid derived suppressor cells did not significantly differ among patient groups. Our findings suggest high pre-treatment frequency of CD39+CD8+ T cells might be a characteristic of HPD. Further investigations in a larger cohort are needed to confirm our results and better delineate the immune landscape of HPD.
Abstract
Hyperprogressive disease (HPD) is a distinct pattern of progression characterized by acceleration of tumor growth after treatment with anti-PD-1/PD-L1 Abs. However, the immunological characteristics have not been fully elucidated in patients with HPD. We prospectively recruited patients with metastatic non-small cell lung cancer treated with anti-PD-1/PD-L1 Abs between April 2015 and April 2018, and collected peripheral blood before treatment and 7-days post-treatment. HPD was defined as ≥2-fold increase in both tumor growth kinetics and tumor growth rate between pre-treatment and post-treatment. Peripheral blood mononuclear cells were analyzed by multi-color flow cytometry to phenotype the immune cells. Of 115 patients, 19 (16.5%) developed HPD, 52 experienced durable clinical benefit (DCB; partial response or stable disease ≥6 months), and 44 experienced non-hyperprogressive progression (NHPD). Patients with HPD had significantly lower progression-free survival (p<0.001) and overall survival (p<0.001). When peripheral blood immune cells were examined, the pre-treatment frequency of CD39+ cells among CD8+ T cells was significantly higher in patients with HPD compared to those with NHPD, although it showed borderline significance to predict HPD. Other parameters regarding regulatory T cells or myeloid derived suppressor cells did not significantly differ among patient groups. Our findings suggest high pre-treatment frequency of CD39+CD8+ T cells might be a characteristic of HPD. Further investigations in a larger cohort are needed to confirm our results and better delineate the immune landscape of HPD.
참고문헌 (26)
- Ribas A, "Cancer immunotherapy using checkpoint blockade", Science, 359, pp.1350~1355 (2018)
- Champiat S, "Hyperprogressive disease : recognizing a novel pattern to improve patient management", Nat Rev Clin Oncol, 15, pp.748~762 (2018)
- Lo Russo G, "Antibody-Fc", FcR interaction on macrophages as a mechanism for hyperprogressive disease in non-small cell lung cancer subsequent to PD-1, Clin Cancer Res, pp.2019, 25[DOI]
- Kamada T, "PD-1+regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer", Proc Natl Acad Sci U S A, 116, pp.9999~10008 (2019)
- Du S, "Blockade of tumor-expressed PD-1 promotes lung cancer growth", OncoImmunology, 7, pp.e1408747~ (2018)
- Kato S, "Hyperprogressors after immunotherapy : analysis of genomic alterations associated with accelerated growth rate", Clin Cancer Res, 23, pp.4242~4250 (2017)
- Kim Y, "Comprehensive clinical and genetic characterization of hyperprogression based on volumetry in advanced non-small cell lung cancer treated with immune checkpoint inhibitor", J Thorac Oncol, 14, pp.1608~1618 (2019)
- Wang X, "The biomarkers of hyperprogressive disease in PD-1", PD-L1blockage therapy, 2020, pp.19, 81~
- Saâda-Bouzid E, "Hyperprogression during anti-PD-1", PD-L1 therapy in patients with recurrent and, Ann Oncol, pp.2017, 28[DOI]
- Champiat S, "Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1", PD-L1, 2017, pp.23, 1920~1928
- Kim KH, "Immune-related adverse events are clustered into distinct subtypes by T-cell profiling before and early after anti-PD-1treatment", OncoImmunology, 9, pp.1722023~ (2020)
- Koh J, "MDSC subtypes and CD39 expression on CD8+T cells predict the efficacy of anti-PD-1 immunotherapy in patients with advanced NSCLC", Eur J Immunol, 50, pp.1810~1819 (2020)
- Bronte V, "Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards", Nat Commun, 7, pp.12150~ (2016)
- Miyara M, "Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3transcription factor", Immunity, 30, pp.899~911 (2009)
- Kim CG, "Hyperprogressive disease during PD-1", PD-L1 blockade in patients with non-small-cell lung cancer, 2019, pp.30, 1104~1113
- Kyung Hwan Kim, "PD-1 blockade-unresponsive human tumor-infiltrating CD8+ T cells are marked by loss of CD28 expression and rescued by IL-15", Cellular & Molecular Immunology, 18(2), pp.385~397 (2021), Springer Science and Business Media LLC[DOI]
- Ferrara R, "Hyperprogressive disease in patients with advanced non-small cell lung cancer treated with PD-1", PD-L1 inhibitors or with single-agent chemotherapy, 2018, pp.4, 1543~1552
- Kim HR, "The ratio of peripheral regulatory T cells to Lox-1+polymorphonuclear myeloid-derived suppressor cells predicts the early response to anti-PD-1 therapy in patients with non-small cell lung cancer", Am J Respir Crit Care Med, 199, pp.243~246 (2019)
- 김경환, "Peripheral Blood Immune Cell-based Biomarkers in Anti-PD-1", PD-L1 Therapy, 2020, pp.20(1), 1~15[DOI]
- Gupta PK, "CD39 expression identifies terminally exhausted CD8+ T cells", PLoS Pathog, 11, pp.e1005177~ (2015)
- Canale FP, "CD39 expression defines cell exhaustion in tumor-infiltrating CD8+T cells", Cancer Res, 78, pp.115~128 (2018)
- Pauken KE, "Overcoming T cell exhaustion in infection and cancer", Trends Immunol, 36, pp.265~276 (2015)
- Kim KH, "The first-week proliferative response of peripheral blood PD-1+CD8+T cells predicts the response to anti-PD-1 therapy in solid tumors", Clin Cancer Res, 25, pp.2144~2154 (2019)
- Huang AC, "T-cell invigoration to tumour burden ratio associated with anti-PD-1 response", Nature, 545, pp.60~65 (2017)
- Jansen CS, "An intra-tumoral niche maintains and differentiates stem-like CD8 T cells", Nature, 576, pp.465~470 (2019)
- Miller BC, "Subsets of exhausted CD8+T cells differentially mediate tumor control and respond to checkpoint blockade", Nat Immunol, 20, pp.326~336 (2019)